A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

NCT06693284 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Primary Malignant Peripheral Nerve Sheath Tumors

Interventions

DRUG: mirdametinib and vorinostat

Sponsor

University of Minnesota